Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

Introduction: Platinum-based chemotherapy was compared to single-agent pembrolizumab in advanced non-small cell lung cancer (NSCLC) with PDL1 > 50% in KEYNOTE-024. In this trial, it was found that patients who received single-agent pembrolizumab had improved progression-free survival in addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittberg, Rebekah, Leung, Bonnie, Shokoohi, Aria, Pender, Alexandra, Wong, Selina, Al-Hashami, Zamzam, Wang, Ying, Ho, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297524/
https://www.ncbi.nlm.nih.gov/pubmed/37366885
http://dx.doi.org/10.3390/curroncol30060402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297524/
https://www.ncbi.nlm.nih.gov/pubmed/37366885
http://dx.doi.org/10.3390/curroncol30060402

Ejemplares similares